AUD 0.2
(11.43%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 | -9.95 Million AUD | 36.43% |
2023 | -15.65 Million AUD | -145.65% |
2022 | -5.99 Million AUD | 24.77% |
2021 | -8.8 Million AUD | 13.99% |
2020 | -5.86 Million AUD | -4.61% |
2019 | -9.5 Million AUD | -67.17% |
2018 | -5.61 Million AUD | 3.33% |
2017 | -6.02 Million AUD | -2.57% |
2016 | -5.59 Million AUD | -54.75% |
2015 | -3.54 Million AUD | -21.16% |
2014 | -3.12 Million AUD | -244.06% |
2013 | -914.72 Thousand AUD | 18.84% |
2012 | -1.16 Million AUD | 55.74% |
2011 | -2.55 Million AUD | -21.1% |
2010 | -2.1 Million AUD | -47.39% |
2009 | -1.43 Million AUD | 3.43% |
2008 | -2.02 Million AUD | 0.0% |
2007 | - AUD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -6.94 Million AUD | 0.0% |
2024 FY | - AUD | 24.58% |
2024 Q4 | -5.54 Million AUD | 0.0% |
2023 Q2 | -6.83 Million AUD | 0.0% |
2023 Q4 | -9.17 Million AUD | 0.0% |
2023 FY | - AUD | -145.65% |
2022 Q2 | -1.02 Million AUD | 0.0% |
2022 Q4 | -5.03 Million AUD | 0.0% |
2022 FY | - AUD | 24.77% |
2021 Q2 | -4.81 Million AUD | 0.0% |
2021 FY | - AUD | 13.99% |
2021 Q4 | -4.28 Million AUD | 0.0% |
2020 Q2 | -6.93 Million AUD | 0.0% |
2020 FY | - AUD | -4.61% |
2020 Q4 | -3.57 Million AUD | 0.0% |
2019 Q2 | -2.96 Million AUD | 0.0% |
2019 FY | - AUD | -67.17% |
2019 Q4 | -5.48 Million AUD | 0.0% |
2018 Q4 | -2.8 Million AUD | 0.0% |
2018 FY | - AUD | 3.33% |
2018 Q2 | -1.67 Million AUD | 0.0% |
2017 Q4 | -3.42 Million AUD | 0.0% |
2017 Q2 | -881.38 Thousand AUD | 0.0% |
2017 FY | - AUD | -2.57% |
2016 Q2 | -2.32 Million AUD | 0.0% |
2016 Q4 | -2.47 Million AUD | 0.0% |
2016 FY | - AUD | -54.75% |
2015 FY | - AUD | -21.16% |
2015 Q4 | -2.1 Million AUD | 0.0% |
2015 Q2 | -1.41 Million AUD | 0.0% |
2014 FY | - AUD | -244.06% |
2014 Q4 | -1.36 Million AUD | 0.0% |
2014 Q2 | -1.75 Million AUD | 0.0% |
2013 Q3 | -228.68 Thousand AUD | 42.43% |
2013 Q2 | -397.24 Thousand AUD | -40.99% |
2013 Q1 | -281.75 Thousand AUD | 0.0% |
2013 FY | - AUD | 18.84% |
2013 Q4 | -445.49 Thousand AUD | -94.81% |
2012 Q4 | - AUD | 100.0% |
2012 Q2 | -281.75 Thousand AUD | 55.74% |
2012 Q1 | -636.6 Thousand AUD | 0.0% |
2012 FY | - AUD | 55.74% |
2012 Q3 | -281.75 Thousand AUD | 0.0% |
2011 Q4 | - AUD | 100.0% |
2011 Q3 | -636.6 Thousand AUD | 0.0% |
2011 Q2 | -636.6 Thousand AUD | -21.11% |
2011 Q1 | -525.62 Thousand AUD | 0.0% |
2011 FY | - AUD | -21.1% |
2010 Q3 | -525.62 Thousand AUD | 0.0% |
2010 Q2 | -525.62 Thousand AUD | -46.63% |
2010 Q4 | - AUD | 100.0% |
2010 Q1 | -358.46 Thousand AUD | 0.0% |
2010 FY | - AUD | -47.39% |
2009 Q2 | -358.46 Thousand AUD | 29.21% |
2009 FY | - AUD | 3.43% |
2009 Q3 | -358.46 Thousand AUD | 0.0% |
2009 Q1 | -506.37 Thousand AUD | 0.0% |
2009 Q4 | - AUD | 100.0% |
2008 Q4 | - AUD | 100.0% |
2008 Q2 | -506.37 Thousand AUD | 0.0% |
2008 FY | - AUD | 0.0% |
2008 Q3 | -506.37 Thousand AUD | 0.0% |
2008 Q1 | - AUD | 0.0% |
2007 Q4 | - AUD | 0.0% |
2007 FY | - AUD | 0.0% |
2007 Q2 | - AUD | 0.0% |
2007 Q3 | - AUD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
EZZ Life Science Holdings Limited | 10.37 Million AUD | 195.901% |
Anatara Lifesciences Ltd | -1.45 Million AUD | -583.082% |
Zelira Therapeutics Limited | -36.44 Million AUD | 72.695% |
Biome Australia Limited | -1.57 Million AUD | -530.458% |
Patrys Limited | -3.49 Million AUD | -184.93% |
Orthocell Limited | -11.68 Million AUD | 14.818% |
Imugene Limited | -147.97 Million AUD | 93.276% |
Noxopharm Limited | -5.94 Million AUD | -67.357% |
PYC Therapeutics Limited | -38.11 Million AUD | 73.896% |
Chimeric Therapeutics Limited | -11.29 Million AUD | 11.943% |
Prescient Therapeutics Limited | -7.18 Million AUD | -38.472% |
Proteomics International Laboratories Limited | -7.88 Million AUD | -26.154% |
CSL Limited | 4.73 Billion AUD | 100.21% |
Arovella Therapeutics Limited | -8.83 Million AUD | -12.646% |
Bio-Gene Technology Limited | -2.97 Million AUD | -234.462% |
Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 119.186% |
Starpharma Holdings Limited | -12.57 Million AUD | 20.886% |
Nanollose Limited | -1.14 Million AUD | -766.817% |
Memphasys Limited | -3.3 Million AUD | -200.818% |
Invex Therapeutics Ltd | -720.44 Thousand AUD | -1281.127% |
NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -453.932% |
Amplia Therapeutics Limited | -4.55 Million AUD | -118.226% |
Botanix Pharmaceuticals Limited | -13.91 Million AUD | 28.515% |
Island Pharmaceuticals Limited | -2.81 Million AUD | -253.08% |
Race Oncology Limited | -14.2 Million AUD | 29.945% |
Nyrada Inc. | -4.59 Million AUD | -116.488% |
Telix Pharmaceuticals Limited | 22.96 Million AUD | 143.326% |
Dimerix Limited | -24.95 Million AUD | 60.133% |
PharmAust Limited | -9.45 Million AUD | -5.274% |
Immutep Limited | -42.87 Million AUD | 76.793% |
Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 77.714% |
Alterity Therapeutics Limited | -19.57 Million AUD | 49.16% |
BTC Health Limited | 1.05 Million AUD | 1042.891% |
Acrux Limited | -7.93 Million AUD | -25.46% |
Neuren Pharmaceuticals Limited | 199.26 Million AUD | 104.994% |
Biotron Limited | -5.04 Million AUD | -97.423% |
Tissue Repair Ltd | -5.77 Million AUD | -72.298% |
AdAlta Limited | -5.3 Million AUD | -87.644% |
Radiopharm Theranostics Limited | -45.37 Million AUD | 78.072% |
Hexima Limited | -995.54 Thousand AUD | -899.475% |
AnteoTech Limited | -11.57 Million AUD | 14.007% |
Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 84.583% |
Recce Pharmaceuticals Ltd | -21.35 Million AUD | 53.404% |
Avecho Biotechnology Limited | -3.24 Million AUD | -206.867% |
Actinogen Medical Limited | -12.92 Million AUD | 22.993% |
Immuron Limited | -6.19 Million AUD | -60.685% |
Argenica Therapeutics Limited | -1.89 Million AUD | -424.36% |